一分钟看懂
这是一项关于前列腺癌的III 期研究，登记的药物或干预包括Opevesostat；Dexamethasone；Fludrocortisone acetate；Hydrocortisone；Abiraterone acetate；Prednisone acetate；Enzalutamide，当前状态为招募中。登记地点显示中国合肥、北京、重庆、福州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Opevesostat；Dexamethasone；Fludrocortisone acetate；Hydrocortisone；Abiraterone acetate；Prednisone acetate；Enzalutamide · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The Second Hospital Of Anhui Medical University ( Site 1633) · 合肥
- Peking University First Hospital-Urology ( Site 1602) · 北京
- Beijing Cancer hospital-Urinary Surgery ( Site 1620) · 北京
- First Medical Center of Chinese PLA General Hospital ( Site 1601) · 北京
- Beijing Cancer Hospital ( Site 1623) · 北京
- Chongqing University Cancer Hospital ( Site 1603) · 重庆
- Southwest Hospital of Third Military Medical University ( Site 1645) · 重庆
- The First Affiliated Hospital Of Fujian Medical University-Urology ( Site 1639) · 福州
- The first affiliated hospital of Guangzhou medical university ( Site 1637) · 广州
- Sun Yat-sen University Cancer Center-Urology Surgery ( Site 1638) · 广州
- Tongji Hospital Tongji Medical,Science & Technology ( Site 1632) · 武汉
- The Central Hospital of Wuhan ( Site 1635) · 武汉
- Hubei Cancer Hospital-Urinary surgery ( Site 1631) · 武汉
- Hunan Cancer Hospital ( Site 1630) · 长沙
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( Site 1615) · 南京
- Nantong Tumor Hospital-Urology ( Site 1609) · 南通
- Wuxi People's Hospital ( Site 1612) · 无锡
- The Second Affiliated Hospital of Xi'an Jiaotong University-Oncology Department ( Site 1619) · 西安
- The First Affiliated Hospital of Xi'an Jiaotong University-Oncology department ( Site 1618) · 西安
- Yantai Yuhuangding Hospital ( Site 1622) · 烟台
- Renji Hosp Shanghai Jiaotong U School of Med ( Site 1624) · 上海
- Huadong Hospital Affiliated to Fudan University-Urology ( Site 1613) · 上海
- West China Hospital, Sichuan University-Urology Surgery ( Site 1642) · 成都
- Nanchong Central Hospital-urology ( Site 1647) · 南充
- The Second Hospital of Tianjin Medical University ( Site 1616) · 天津
- Xinjiang Medical University Cancer Hospital - Urumqi-Urology ( Site 1644) · 乌鲁木齐
- Yunnan Province Cancer Hospital ( Site 1643) · 昆明
- Zhejiang Provincial People's Hospital-Urology ( Site 1641) · 杭州
- The First Hospital of Jiaxing-urology ( Site 1605) · 嘉兴
- Ningbo First Hospital-Urology ( Site 1608) · 宁波
- The First Affiliated Hospital of Wenzhou Medical University ( Site 1604) · 温州
公开的入选条件
- The main inclusion criteria include but are not limited to the following:
- * Have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell histology
- * Has prostate cancer progression while receiving androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months before screening
- * Has current evidence of distant metastatic disease (M1 disease) documented by either bone lesions on bone scan and/or soft tissue disease shown by computed tomography (CT)/magnetic resonance imaging (MRI)
- * Has disease that progressed during or after treatment with one next-generation hormonal agent (NHA) for hormone sensitive prostate cancer (HSPC) (metastatic hormone-sensitive prostate cancer \[mHSPC\] or non-metastatic hormone-sensitive prostate cancer \[nmH
- * Has had prior treatment with poly (ADP-ribose) polymerase inhibitor (PARPi) or were deemed ineligible to receive treatment by the investigator or have refused PARPi treatment
- * Has ongoing androgen deprivation therapy (ADT) with serum testosterone \<50 ng/dL (\<1.7 nM)
- * Has an eastern clinical oncology group (ECOG) performance status of 0 or 1 assessed within 10 days before randomization
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06136650；登记信息更新于 2026-09-17。